Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Suk-Joong Oh"'
Autor:
Youngwoo Jeon, Duk-Hwan Yang, Suk-Joong Oh, Jin-Hee Park, Jung-Ah Kim, Sung-Young Kim, Chul-Won Choi, Won-Sik Lee, In-Ho Kim, Yeung-Chul Mun, Gi June Min, Ki-Seong Eom, Seok-Goo Cho
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundA chemotherapy of rituximab, fludarabine and cyclophosphamide (R-FC) has been accepted as a promising frontline chemotherapy in selected patients with chronic lymphocytic leukemia (CLL). Although R-FC regimen is a relatively dose-dense regi
Externí odkaz:
https://doaj.org/article/9f7b900f3cdc4292a9d9e4e7c2b615a9
Autor:
Sung‐Eun Lee, Jee Hyun Kong, Soo‐Hyun Kim, Eun‐Jung Jang, Nack‐Gyun Chung, Bin Cho, Suk Joong Oh, Hae‐Eok Jung, Ho‐Joong Youn, Woo‐Baek Chung, Dong‐Wook Kim
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1515-1524 (2021)
Abstract Background We investigated the feasibility of the clinical application of non‐invasive transthoracic echocardiography for diagnosis of pulmonary arterial hypertension induced by dasatinib (D‐PAH) in chronic myeloid leukemia (CML). Method
Externí odkaz:
https://doaj.org/article/4ae491261bd24ff6a75b301ac9197e71
Autor:
Min Kyu Park, Chang Myeon Song, Hae jin Park, Yoon-Young Choi, Young-Jun Lee, Jae Kyung Myung, Suk Joong Oh, Seong Oh Park, Hye Young Seo, Jin Won Lee, Yong-Bae Ji, Kyung Tae
Publikováno v:
Korean Journal of Otorhinolaryngology-Head and Neck Surgery. 65:806-812
Background and Objectives The head and neck multidisciplinary team (MDT) approach plays a crucial role in bringing together the ideas of various medical professionals. This study aimed to evaluate the early characteristics of the MDT approach for hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eca3e5cb085b35f531d13e8ef798ced
https://doi.org/10.3342/kjorl-hns.2022.00976
https://doi.org/10.3342/kjorl-hns.2022.00976
Autor:
Seo-Yeon Ahn, Sang Kyun Son, Gyu Hyung Lee, Inho Kim, June-Won Cheong, Won Sik Lee, Byung Soo Kim, Deog-Yeon Jo, Chul Won Jung, Chu Myoung Seong, Jae Hoon Lee, Young Jin Yuh, Min Kyoung Kim, Hun-Mo Ryoo, Moo-Rim Park, Su-Hee Cho, Hoon-Gu Kim, Dae Young Zang, Jinny Park, Hawk Kim, Seryeon Lee, Sung-Hyun Kim, Myung Hee Chang, Ho Sup Lee, Chul Won Choi, Jihyun Kwon, Sung-Nam Lim, Suk-Joong Oh, Inkyung Joo, Dong-Wook Kim
Publikováno v:
Blood Research. 57:144-151
Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This study aimed to confirm the safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adbe1b42a8bd232c685c0439a8215668
https://doi.org/10.5045/br.2022.2021137
https://doi.org/10.5045/br.2022.2021137
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Supplementary Methods, Supplementary Figure Legends, Supplementary Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0494cbfb70206985634a6c110a3bed99
https://doi.org/10.1158/1078-0432.22466123.v1
https://doi.org/10.1158/1078-0432.22466123.v1
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Kaplan-Meier estimated progression-free survival (PFS) in the intention-to-treat population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03a5ba45cac3052fa7019dc560fa4fba
https://doi.org/10.1158/1078-0432.22466129
https://doi.org/10.1158/1078-0432.22466129
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Major molecular response by 12 months, by Sokal risk group. bid, twice daily; MMR, major molecular response (defined as BCR-ABL1 transcript level {less than or equal to}0.1% [MR3.0]); qd, daily.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3efd1db8b4ec98559ea8fcd928730fb1
https://doi.org/10.1158/1078-0432.22466132.v1
https://doi.org/10.1158/1078-0432.22466132.v1
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9374f34c079b8a9da3ff6c858e2b66a3
https://doi.org/10.1158/1078-0432.c.6526247
https://doi.org/10.1158/1078-0432.c.6526247
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (c) Radotinib 300 mg bid (n = 79 patients with evaluable molecular data at 3 months).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea270c05ca497a09533ec742014d7bc
https://doi.org/10.1158/1078-0432.22466135
https://doi.org/10.1158/1078-0432.22466135
Autor:
Yoon Jung Jang, Sang Moo Lim, Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Seung‐Sook Lee, Cheolwon Suh, Dok Hyun Yoon, Inho Kim, Seung‐Hyun Nam, Mark Hong Lee, Jong Ho Won, Jee Hyun Kong, Seong Hyun Jeong, Suk Joong Oh, Keon Woo Park, Jae Joon Han, Moo‐Kon Song, Sung Hyun Yang, Im Il Na, Hyo‐Rak Lee, Dong‐Yeop Shin, Hye Jin Kang
Publikováno v:
Asia-Pacific Journal of Clinical Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53c1e4538e5f90331e029e9aa4e77e27
https://doi.org/10.1111/ajco.13932
https://doi.org/10.1111/ajco.13932